| __timestamp | Alnylam Pharmaceuticals, Inc. | MiMedx Group, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 190249000 | 7050000 |
| Thursday, January 1, 2015 | 276495000 | 8413000 |
| Friday, January 1, 2016 | 382392000 | 12038000 |
| Sunday, January 1, 2017 | 390635000 | 17900000 |
| Monday, January 1, 2018 | 505420000 | 15765000 |
| Tuesday, January 1, 2019 | 655114000 | 11140000 |
| Wednesday, January 1, 2020 | 654819000 | 11715000 |
| Friday, January 1, 2021 | 792156000 | 17344000 |
| Saturday, January 1, 2022 | 883015000 | 22829000 |
| Sunday, January 1, 2023 | 1004415000 | 12665000 |
| Monday, January 1, 2024 | 1126232000 |
Unleashing the power of data
In the ever-evolving world of biotechnology, research and development (R&D) investments are the lifeblood of innovation. Over the past decade, Alnylam Pharmaceuticals, Inc. has consistently outpaced MiMedx Group, Inc. in R&D spending, underscoring its commitment to pioneering advancements. From 2014 to 2023, Alnylam's R&D expenses surged by over 400%, peaking in 2023 with a remarkable 1 billion dollars. In contrast, MiMedx's investment grew modestly, with a peak in 2022 at just 23 million dollars. This stark difference highlights Alnylam's aggressive strategy to lead in RNA interference therapeutics, while MiMedx focuses on regenerative medicine. As the biotech landscape continues to shift, these investments will likely shape the future of medical breakthroughs, offering a glimpse into the priorities and potential of these industry players.
Analyzing R&D Budgets: Zoetis Inc. vs MiMedx Group, Inc.
Research and Development Expenses Breakdown: Alnylam Pharmaceuticals, Inc. vs Summit Therapeutics Inc.
Comparing Innovation Spending: Alnylam Pharmaceuticals, Inc. and Viatris Inc.
R&D Insights: How Alnylam Pharmaceuticals, Inc. and MannKind Corporation Allocate Funds
Research and Development Investment: Alnylam Pharmaceuticals, Inc. vs Arrowhead Pharmaceuticals, Inc.
R&D Spending Showdown: Alnylam Pharmaceuticals, Inc. vs Geron Corporation
Comparing Revenue Performance: Alnylam Pharmaceuticals, Inc. or MiMedx Group, Inc.?
Research and Development Investment: PTC Therapeutics, Inc. vs MiMedx Group, Inc.
Comparing Innovation Spending: Celldex Therapeutics, Inc. and MiMedx Group, Inc.
Research and Development Investment: BioCryst Pharmaceuticals, Inc. vs MiMedx Group, Inc.
R&D Spending Showdown: Xencor, Inc. vs MiMedx Group, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Evotec SE and MiMedx Group, Inc.